(DuPont) -- DuPont leaders recently told security analysts and investors that the company is executing a rapid commercialization strategy in its Applied BioSciences (ABS) business for a diverse portfolio of high-performance, renewable products that address the needs of large markets. The company has set goals for the ABS business of $1 billion in revenue and $250 million in pretax earnings by 2015.
⌠DuPont is uniquely positioned to lead in industrial biotechnology. We are connecting our core technology capabilities to markets that can be transformed by our science, and this strategy is beginning to pay off, said Tom Connelly, DuPont executive vice president and chief innovation officer. ⌠The Applied BioSciences portfolio is developing solutions to reduce dependence on fossil fuels and continues to be one of the most significant growth opportunities in the company's history.
Investors were invited to Tennessee to see the business' first commercial biomaterials facility and its first demonstration biofuels facility, each of which is bringing DuPont ABS technology to market. The DuPont Tate & Lyle Bio Products facility in Loudon, Tenn., produces 100 million pounds annually of Bio-PDO. The DuPont Danisco Cellulosic Ethanol demonstration facility in Vonore, Tenn., is preparing this second-generation biofuel technology for market.